Cellular adoptive immunotherapy after bone marrow transplantation.
Explore this paper's citation graph
Summary
Cellular adoptive immunotherapy has been broadly used to describe the transfer of effector cells of the immune system to treat malignant or infectious diseases, but several impediments have hindered clinical applications and impacted on the success of the initial attempts at adoptive therapy for human diseases.
- Type
- review
- Published
- 1995-01-01
- Cited by
- 23
- References
- 187
- OpenAlex
- https://openalex.org/W45376543
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:41104937
Keywords
Effector, Adoptive cell transfer, Adoptive immunotherapy, Immunotherapy, Immune system
References
- The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes.
- Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis.
- Epstein-Barr virus lymphoproliferation after bone marrow transplantation.
- Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation.
- Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
- Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells.
- Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation.
- The immune response to influenza infection.
- Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.
- Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes.
- Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines.
- Graft-versus-leukemia reactions after bone marrow transplantation.
- Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.
- Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo.
- Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2.
- The suppression of Epstein-Barr virus infection in vitro occurs after infection but before transformation of the cell.
- Augmentation of human natural cell-mediated cytotoxicity by recombinant human interleukin 2.
- Alloreactive murine CD8+ T cell clones secrete the Th1 pattern of cytokines.
- In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities.
- Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin.
Cited by
- Use of peptides and peptide libraries as T-cell stimulants in flow cytometric studies.
- Role of cellular immunity in protection against HIV infection.
- Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation.
- Review on Immunotherapy Strategies against Infectious and Noninfectious Diseases
- T cell‐based immunotherapy for cancer: A virtual reality?
- Induction of Pluripotent Protective Immunity Following Immunisation with a Chimeric Vaccine against Human Cytomegalovirus
- Immunobiology and immunotherapy of head and neck cancer
- Targeting Cytomegalovirus-Infected Cells Using T Cells Armed with Anti-CD3 × Anti-CMV Bispecific Antibody
- Genetic, cellular and immune approaches to disease therapy: past and future
- Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses
- Measurement of Anti-Human Cytomegalovirus T Cell Reactivity in Transplant Recipients and Its Potential Clinical Use: A Mini-Review
- Autologous Bone Marrow Transplants to Hematopoietic Stem Cell Support with Peripheral Blood Stem Cells: A Historical Perspective
- Ad-gBCMVpoly: A novel chimeric vaccine strategy for human cytomegalovirus-associated diseases.
- High‐resolution cell division tracking demonstrates the Flt3‐ligand‐dependence of human marrow CD34+CD38− cell production in vitro
- Anti-Viral Responses Following LLME Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease
- T lymphocyte therapy of cancer.
- Vaccination strategies for neuro-oncology.
- Spatial Dynamics and the Mechanoresponse in CD4+ T Cell Activation
- Advances and challenges: dendritic cell vaccination strategies for glioblastoma
- Immunotherapy strategies against infectious and noninfectious diseases: Review
Related papers
- Adoptive cellular immunotherapy for cancer
- CMV-specific immunotherapy.
- Adoptive immunotherapy of cancer: accomplishments and prospects.
- Adoptive transfer of virus-directed T cells: will this fly for flu?
- Modelling pulsed immunotherapy of tumour-immune interaction
- Adoptive immunotherapy for cancer: building on success
- A long road of T-cells to cure cancer: from adoptive immunotherapy with unspecific cellular products to donor lymphocyte infusions and transfer of engineered tumor-specific T-cells.